Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics
WHO and partners have learnt from the mis-steps in the response to the 2009 H1N1 influenza pandemic1 and established the Access to COVID-19 Tools (ACT) Accelerator to promote equitable access to vaccines, therapeutics, and diagnostics.2 However, many high-income countries already have bilateral agreements with manufacturers of COVID-19 vaccines.3 The COVAX Facility of the ACT Accelerator has agreements to access 2 billion doses of WHO pre-qualified vaccines during 2021, but this represents only 20% of the vaccine needs of participating countries.4 Most low-income and middle-income countries (LMICs) face difficulties in accessing and delivering vaccines and therapeutics for COVID-19 to their populations.5 COVAX will require decisive action by Gavi, the Vaccine Alliance, WHO, and the Coalition for Epidemic Preparedness Innovations (CEPI), supported by the countries they serve and with financing for vaccine purchasing, to ensure people worldwide have equitable access to COVID-19 vaccines.6, 7, 8 [Click to read more.]
Figueroa, J.P., Bottazzi, M.E., Hotez, P., Batista, C., Ergonul, O., Gilbert, S., Gursel, M., Hassanain, M., Kim, J.H., Lall, B., Larson, H., Naniche, D., Sheahan, T., Shoham, S., Wilder-Smith, A., Strub-Wourgaft, N., Yadav, P., & Kang, G. Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. (2021). Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. The Lancet, 397(10274), 562-564. doi:10.1016/S0140-6736(21)00242-7
Prof. Mayda Gürsel
|Web of Science/Publons Researcher ID: H-1812-2012|
|email@example.com||Scopus Author ID: 6701661028|
|About the author||ORCID: 0000-0003-0044-9054|
Figueroa, J.P., Bottazzi, M.E., Hotez, P., Batista, C., Ergonul, O., Gilbert, S., Hassanain, M., Kim, J.H., Lall, B., Larson, H., Naniche, D., Sheahan, T., Shoham, S., Wilder-Smith, A., Strub-Wourgaft, N., Yadav, P., & Kang, G.
MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd, a commercial vaccine manufacturer for scale-up, production, testing, and licensure. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. SG has a ChAdOx1 nCoV-19 patent application licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JHK reports personal fees from SK biosciences. GK is an Independent Director of Hilleman Laboratories Private Limited and Vice Chair of the Board of CEPI. HL reports grants and honoraria for training talks from GlaxoSmithKline, and grants and honoraria from Merck as a member of the Merck vaccine confidence advisory board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Diseases, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fast Grants. SS reports grants from the US Department of Defense, Bloomberg Foundation, State of Maryland, Ansun, Astellas, Cidara, F2G, T2, Shire, Shionogi, and Scynexis; personal fees from Acidophil, Amplyx, Janssen, Karyopharm, Intermountain Health, and Immunome; grants and personal fees from Merck, Reviral outside the submitted work. All other authors declare no competing interests. The authors' views and opinions in this Comment do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. We thank Jeffrey Sachs, Chair of the Lancet COVID-19 Commission, and Yanis Ben Amor, member of the Secretariat of this Commission, for their invaluable review and feedback.